SAB

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

Retrieved on: 
Monday, March 4, 2024
University of Texas System, Bangladesh Technical Education Board, School, Boston Medical Center, Dementia, NIH, University, Cerebrovascular disease, SAB, Stroke, Frank, Radiology, History, Biomedical sciences, Clinical, UNC, Clinical trial, Knowledge, McGovern Medical School, Pediatrics, Research, BMC, Pharmaceutical industry

BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB). Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.

Key Points: 
  • Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
  • The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.
  • “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.
  • “This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases.

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Alnylam Pharmaceuticals, Senior, Enzyme, (glutamate—ammonia-ligase) adenylyltransferase, Doctor of Philosophy, Gene editing, Biotechnology, Roche, Pharmaceutical manufacturing, SAB, Telephone, McGill University, Phosphorylation, Research and development, Growth, DNA, ECO, RNA, Medication, Food, Nucleotide, Element, Administration, Exocrine pancreatic insufficiency, Central Waqf Council, Protein, Net, Small RNA, MBBS, RNA interference, Masad Damha, Video game

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • Including enzyme sales related to PAXLOVID™, total revenues were $26.6 million in fourth quarter 2023 compared to $30.4 million in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product revenues were $18.1 million in fourth quarter 2023 compared to $23.3 million in fourth quarter 2022.
  • Product gross margin, excluding enzyme sales related to PAXLOVID™, was 71% for fourth quarter 2023 compared to 44% in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product gross margin for fourth quarter 2023 was 84% compared to 64% in fourth quarter 2022.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Retrieved on: 
Wednesday, February 28, 2024
ASRS, Senior, Paris Diderot University, SAB, Reno 1868 FC, Growth, Visual acuity, University, DED, Telecanthus, Organization, Principal, Teaching hospital, Retina, Anthropology, Diabetic retinopathy, Therapy, OCS, Inflammation, CSO, DME, American Academy, Simmons University, M.A, Clinical research, ASCRS, Society, Cerebral edema, Eastern Virginia Medical School, Patient, Partner (business rank), Medicine, Pharmaceutical industry

In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.

Key Points: 
  • In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.
  • “2024 promises to be another exciting year for Oculis as we advance our late-stage clinical development programs.
  • I am certain that the extensive experience each of them brings will be invaluable to Oculis,” said Riad Sherif, M.D., Chief Executive Officer of Oculis.
  • Oculis also announced today key executive appointments to bolster its leadership and scientific advisory teams.

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, MAIA, Gilead Sciences, Medicine, ASH, ASCO, SAB, FDA, Drug development, AbbVie, European Hematology Association, Mantle cell lymphoma, Pleasure, Kite Pharma, Hematology, EHA, University, Society, University of Bern, Patient, NK, Pharmacyclics, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

Retrieved on: 
Wednesday, February 21, 2024
SAB, FDA, LH, Growth, Sale, HP, Commerce, Labcorp, Central Waqf Council, Workforce, IBS, Management

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB).

Key Points: 
  • IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB).
  • Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCorp” (NYSE: LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product.
  • Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world’s largest diagnostics clinical laboratories, boasting $7B in annual revenues, over 2,000 locations, and a workforce of 36,000 employees.
  • Zack Irani, CEO of Biomerica, expressed confidence in Mr. Huff’s appointment, stating, “Gary's remarkable career in healthcare and clinical laboratories, particularly as LabCorp’s Diagnostics CEO, showcases his exceptional abilities.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Tuesday, February 20, 2024
Organic chemistry, Therapy, Bachelor of Science, Cancer, Alnylam Pharmaceuticals, Lakehead University, Senior, Enzyme, Doctor of Philosophy, Gene editing, Biotechnology, SAB, McGill University, Biocatalysis, Research and development, ANA, ECO, Masad, International Society, Oligonucleotide, Codexis, RNA, Nucleic acid, Central Waqf Council, Patient, Texas A&M University, About us, Infection, Editorial board, Publication, Development, Laboratory, Masad Damha, Management

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
Thursday, February 22, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Organic chemistry, Viral, Senior, Janssen Pharmaceuticals, Dartmouth College, SAB, Neuroscience, Beclabuvir, PTC Therapeutics, University, RNA, Jan Vansina, RSV, HIV-1, Atomic, Johnson & Johnson, Stroke, Bristol Myers Squibb, MBA, BMS, Therapy, Journal, HCV, PTC, Drug discovery, Meanwell, McArdle Laboratory, American Academy, Royal Society, Daclatasvir, Harvard University, Asunaprevir, Doctor of Philosophy, Thrombosis, Rutgers University, Patient, Outline of physical science, American Chemical Society, Deep learning, Publication, Cancer, Medicinal chemistry, Pharmaceutical industry

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

Dr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy

Retrieved on: 
Friday, March 8, 2024
Therapy, DNA, Multimedia, Chemistry, Library, Synthetic biology, SAB, Deletion, Harvard University, Drug discovery, PACE, Broad Institute, Howard Hughes Medical Institute, Health, Patient, Protein, Knowledge, Publication, Biology, Research, Medical device

PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).

Key Points: 
  • PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).
  • "We are thrilled to have Dr. David Liu on board to guide our initiatives," said Sherry Shao, Rotating Chief Executive Officer of GenScript.
  • "Dr. Liu's extensive knowledge and innovation will be instrumental to GenScript as we strive to enhance our platform with the aim of accelerating transformative breakthroughs to patients."
  • With Dr. Liu's addition, GenScript's SAB now encompasses leading experts across the full spectrum of genome editing and cell and gene therapy.

Nutraland USA, Inc. Forms Scientific Advisory Board with Esteemed Panel of Experts

Retrieved on: 
Thursday, March 7, 2024
SAB, Research, Management

IRVINE, Calif., March 7, 2024 /PRNewswire/ -- Nutraland USA, Inc., a leading provider of innovative, plant-based and science-backed nutraceuticals, proudly announces the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • IRVINE, Calif., March 7, 2024 /PRNewswire/ -- Nutraland USA, Inc., a leading provider of innovative, plant-based and science-backed nutraceuticals, proudly announces the formation of its Scientific Advisory Board (SAB).
  • Gene Bruno, Chief Science Officer at Nutraland USA, emphasized the importance of assembling a board with profound understanding and experience in nutraceuticals.
  • The establishment of the Scientific Advisory Board marks a significant milestone in Nutraland's journey toward excellence in nutraceutical research, development, and distribution.
  • With this esteemed panel guiding its scientific endeavors, Nutraland USA reaffirms its commitment to delivering premium-quality, science-backed products to its customers.

Immunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy Breakthroughs

Retrieved on: 
Wednesday, March 6, 2024
Bone marrow, Multimedia, Immunotherapy, SAB, FDA, Keio Medical Science Prize, University, Health, Dan, Patient, Knowledge, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

PISCATAWAY, N.J., March 6, 2024 /PRNewswire/ -- GenScript, a leading provider of life science research and application services, today proudly announced that Dr. Carl June, a distinguished figure in the field of immunotherapy, has joined the company's scientific advisory board (SAB).

Key Points: 
  • "Dr. June's vast experience in CAR T-cell therapy for cancer will provide invaluable insights for GenScript's initiatives," said Sherry Shao, Rotating Chief Executive Officer of GenScript.
  • "We are honored to welcome Dr. Carl June to the GenScript team and are eager to leverage his expertise as we develop more tools and solutions, particularly in the areas of cell and gene therapy."
  • "The SAB is composed of scientific leaders whose seminal research has significantly advanced the fields of genome editing and cell and gene therapy," said Ray Chen, Ph.D., President of the Life Science Group at GenScript.
  • With the addition of Dr. June, GenScript's SAB comprises leading experts across the spectrum of genome editing and cell and gene therapy.